{
  "ptid_time": "033_S_1116_2008-06-20",
  "img_path": "/data/qiuhui/data/adni/images/033_S_1116/2008-06-20/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 68,954 mm³, 46.7% above the reference mean. With a Z-score of 1.36 (91.2th percentile), this represents mild enlargement; hippocampal volume measures 4,801 mm³, 31.1% below the reference mean. With a Z-score of -2.69 (0.4th percentile), this represents significant atrophy; whole brain volume measures 952,427 mm³, 7.5% below the reference mean. With a Z-score of -0.98 (16.4th percentile), this represents normal volume ; entorhinal cortex volume measures 2,479 mm³, 37.5% below the reference mean. With a Z-score of -2.46 (0.7th percentile), this represents significant atrophy; fusiform gyrus volume measures 15,225 mm³, 15.7% below the reference mean. With a Z-score of -1.36 (8.7th percentile), this represents mild atrophy; middle temporal gyrus volume measures 18,221 mm³, 9.7% below the reference mean. With a Z-score of -0.87 (19.3th percentile), this represents normal volume . ",
  "text_data": "Age is 84.9 years. Gender is Male. Education: 18 years. MMSE: 28.0. Laboratory findings: Monocytes: 0.65 (significant elevated); Monocytes: 10.00 (significant elevated); GGT: 41.00 (significant elevated); Creatinine (Rate Blanked): 1.40 (significant elevated). APOEε4 alleles: 2.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in the hippocampus and entorhinal cortex, both key regions affected in Alzheimer's disease, along with mild ventricular enlargement. Despite the high MMSE score (28/30), the structural changes, combined with advanced age and APOE4 homozygosity (high genetic risk), strongly suggest neurodegeneration.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely prodromal Alzheimer’s given biomarker profile).  \n**Confidence:** **High** (due to clear atrophy in AD-vulnerable regions + APOE4 risk, though MMSE is atypically preserved).  \n\n*Note:* The discrepancy between imaging and MMSE may reflect cognitive reserve or early-stage pathology before significant functional decline. Follow-up with more sensitive cognitive tests (e.g., MoCA) and CSF/PET biomarkers would strengthen certainty.",
  "timestamp": "2025-07-26T05:30:41.052398"
}